E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006279 |
E.1.2 | Term | Breast neoplasm |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
 To assess whether a maintenance therapy with trastuzumab is superior in terms of PFS to no further trastuzumab treatment in patients with locally advanced and/or metastatic breast cancer over expressing HER2 and not progressed to a first line chemotherapy containing trastuzumab (maintenance study)  To assess whether a second line chemotherapy with trastuzumab after failure of a first line regimen of chemotherapy plus trastuzumab is superior in terms of OS to chemotherapy alone in patients with locally advanced and/or metastatic breast cancer over expressing HER2 (2nd line study) |
|
E.2.2 | Secondary objectives of the trial |
 To assess whether a maintenance therapy with trastuzumab is superior in terms of OS to no further trastuzumab treatment in patients with locally advanced and/or metastatic breast cancer over expressing HER2 and not progressed to a first line chemotherapy containing trastuzumab (maintenance study) To assess whether a second line chemotherapy with trastuzumab after failure of a first line regimen of chemotherapy plus trastuzumab is superior in terms of PFS to chemotherapy alone in patients with locally advanced and/or metastatic breast cancer over expressing HER2 (2nd line study) To evaluate the safety profiles of the treatments |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
 >18 years of age. Patients older of 70 years of age are eligible on the basis of an individual risk-benefit assessment by the investigator  Histologically confirmed breast cancer with locally advanced and/or metastatic disease  Over expression of HER2 (3+) as determined by IHC or amplification of HER2/c-erbB2 by FISH/CISH of the primary tumour or of a metastasis  Assessable disease. The presence of measurable disease is not needed for enrolment. Patients with bone lesions, ascites and pleural effusion as only sites of disease are considered eligible  Completion of a first line chemotherapy in association with trastuzumab given for at least 6 months for advanced disease. The last dose of trastuzumab should have to be given within 6 weeks prior to randomisation for treatments given with a 3 weekly schedule or within 3 weeks if a weekly schedule was used (only for maintenance study)  Progressive disease during or within 6 months from the completion of a first line chemotherapy plus trastuzumab for advanced disease or within 6 months from the completion of an adjuvant treatment for early disease (only for 2nd line study). Patients progressing more than 6 months after the completion of a first line trastuzumab-containing regimen should be re-treated with the previous regimen and included in 2nd line study after evidence of progression.  Signed written informed consent obtained prior to any study specific study procedures |
|
E.4 | Principal exclusion criteria |
Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab.  >18 years of age. Patients older of 70 years of age are eligible on the basis of an individual risk-benefit assessment by the investigator  Histologically confirmed breast cancer with locally advanced and/or metastatic disease  Over expression of HER2 (3+) as determined by IHC or amplification of HER2/c-erbB2 by FISH/CISH of the primary tumour or of a metastasis  Assessable disease. The presence of measurable disease is not needed for enrolment. Patients with bone lesions, ascites and pleural effusion as only sites of disease are considered eligible  Completion of a first line chemotherapy in association with trastuzumab given for at least 6 months for advanced disease. The last dose of trastuzumab should have to be given within 6 weeks prior to randomisation for treatments given with a 3 weekly schedule or within 3 weeks if a weekly schedule was used (only for maintenance study)  Progressive disease during or within 6 months from the completion of a first line chemotherapy plus trastuzumab for advanced disease or within 6 months from the completion of an adjuvant treatment for early disease (only for 2nd line study). Patients progressing more than 6 months after the completion of a first line trastuzumab-containing regimen should be re-treated with the previous regimen and included in 2nd line study after evidence of progression.  Signed written informed consent obtained prior to any study specific study procedures  ECOG-PS >2  Pregnant or lactating women. Women of childbearing potential must implement adequate contraceptive measures  Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin, or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years.  Baseline LVEF <50% (measured by echocardiography or MUGA) performed within 4 weeks prior to randomisation. History of documented congestive heart failure, angina pectoris requiring antianginal medication, evidence of transmural infarction ECG, poorly controlled hypertension (systolic > 180 mmHg or diastolic > 100 mmHg); clinically significant valvular heart disease; high-risk uncontrolled arrhythmias  Presence of CNS metastases, not amenable to curative therapy. Patients with previously treated CNS metastases must be asymptomatic and stable at radiological imaging from at least 3 months  Patients with dyspnoea at rest due to malignant or other disease, or who require supportive oxygen therapy. Patients with pre-existing lung disease or advanced pulmonary involvement may be at increased risk of serious toxicities with trastuzumab and should be evaluated carefully before entry into the study  Concomitant chemotherapy with anthracyclines, including liposomial drugs (only for 2nd line study)  Treatment with any investigational drug within 30 days before beginning of enrolment in the trial  History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of trastuzumab |
|
E.5 End points |
E.5.1 | Primary end point(s) |
 PFS is defined as the time from the date of randomisation up to the date of first progression, second primary malignancy or death from any cause, whichever comes first. Subjects who have not progressed or died while on study will be censored at the last disease assessment date.  OS is defined as the time from the date of randomisation to the date of death from any cause. Subjects who were not reported as having died at the time of the analysis will be censored at the date they were last known to be alive.  Toxicity, graded according to the NCI-CTAE version 3.0  Frequency and nature of serious adverse reactions  Premature withdrawals During the course of the trial, an independent Data and Safety Monitoring Committee (DSMC) will advise the Steering Committee on efficacy and safety aspects of the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
assunzione del farmaco - interruzione assunzione |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |